Spain Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Spain Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Spain Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The Spanish pharmaceutical market has struggled in the face of the economic crisis , but is now expected to return to pre-crisis levels in the coming years. Despite being an economic outperformer in Western Europe, market growth will remain slow but steady through the forecasted period, sustained by a n aging population . However, we believe the government will continue with cost-efficient policies aimed at the pharmaceutical sector in order to control rising healthcare bills.

Headline Expenditure Projections

  • Pharmaceuticals: EUR25.15bn (USD27.70bn) in 2015 to EUR25.61bn (USD27.40bn) in 2016; +1.7% in local currency terms and -1.1% in US dollar terms. Forecast unchanged from last quarter.

  • Healthcare: EUR90.80bn (USD99.88bn) in 2015 to EUR92.56bn (USD99.04bn) in 2016; +1.9% in local currency terms and -0.8% in US dollar terms. Forecast revised downwards slightly from last quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Spain 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 33.111 27.703 27.404 28.619 30.350 32.096 32.516
Pharmaceutical sales, % of GDP 2.37 2.28 2.22 2.18 2.13 2.07 2.01
Pharmaceutical sales, % of health expenditure 27.5 27.7 27.7 27.5 27.2 26.9 26.4
Health spending, USDbn 120.346 99.877 99.041 103.963 111.376 119.440 123.074

Risk/Reward Index

In BMI's Pharmaceutical Risk/Reward Index for Q216, Spain scored 67.5 and ranked 12th out of the 15 countries surveyed in Western Europe - just below the Netherlands (70.2). While Spain offers investors positive features, such as its large drug market, it also has problems, such as the government's focus on cost containment, low population growth, cumbersome bureaucracy and provincial differences regarding drug regulations and reimbursement.

Key Trends And Developments

  • Eisai has entered into an agreement with Esteve to co-promote Fycompa (perampanel) in Spain from February 2016.

  • In February 2016, Spain-based pharmaceutical company Almirall completed the purchase of Swiss Poli Group in a deal worth EUR365mn (USD385.8mn).

  • In February 2016, Grifols reported net revenues of EUR3.93bn (USD4.27bn) in 2015, growing 17.3% from the previous year. The group posted a profit of EUR532mn (USD578mn), representing a 13.2% increase from 2014.

  • In December 2015, the government approved the Royal Decree 1090/2015, which regulates clinical trials with drugs, ethics committees and the Spanish Clinical Trials Register.

  • In November 2015, Spanish pharmaceutical industry group Farmaindustria and the Ministries of Finance and Health signed a 12-month collaboration deal, with the aim of making the Spanish national health services more sustainable.

BMI Economic View

The Spanish economy will remain one of the fastest growing in the eurozone in 2016, in spite of the country's ongoing political impasse. A further leg down in oil prices has prompted us to revise up our real GDP forecasts to 2.5% in 2016 and 2.2% the following year, from 2.4% and 2.1% previously.

BMI Political View

Attempts by the People's Party to form a coalition government following the Spanish December 2015 general election have been clouded by Catalonia's failure to elect a regional president. A fractured secessionist movement reduces the perceived need for Spain's traditional parties to work together in a coalition arrangement.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Spain 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Spain 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Spain 2012-2020)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Spain 2012-2020)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Spain 2012-2020)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Spain 2012-2020)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Spain 2012-2020)
21
Generic Drug Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Spain 2012-2020)
24
OTC Drug Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Spain 2012-2020)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Spain 2014-2020)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (Spain 2014-2020)
28
Pharmaceuticals & Healthcare Risk/Reward Index
29
Western Europe Risk/Reward Index
29
Spain Risk/Reward Index
34
Rewards
34
Risks
34
Regulatory Review
36
Intellectual Property Issues
37
Parallel Trade
38
OTC Medicines
39
Generic Medicines
40
Pricing Regime
40
Reference Pricing System
42
Reimbursement Regime
45
Market Overview
46
Epidemiology
47
Healthcare Sector
49
Table: Regional Public Hospital Debt - Values In EURmn
50
Table: Healthcare Resources (Spain 2010-2015)
52
Table: Healthcare Personnel (Spain 2010-2015)
52
Table: Healthcare Activity (Spain 2010-2015)
53
Research & Development
53
Clinical Trials
54
Competitive Landscape
56
Research Based Industry
56
Generic Drug Sector
57
Table: Multinational Market Activity
58
Biotechnology Sector
59
Pharmaceutical Retail
61
Company Profile
64
Almirall
64
Esteve
67
Demographic Forecast
70
Demographic Outlook
70
Table: Population Headline Indicators (Spain 1990-2025)
71
Table: Key Population Ratios (Spain 1990-2025)
71
Table: Urban/Rural Population & Life Expectancy (Spain 1990-2025)
72
Table: Population By Age Group (Spain 1990-2025)
72
Table: Population By Age Group % (Spain 1990-2025)
73
Glossary
75
Methodology
77
Pharmaceutical Expenditure Forecast Model
77
Healthcare Expenditure Forecast Model
77
Notes On Methodology
78
Risk/Reward Index Methodology
79
Index Overview
80
Table: Pharmaceutical Risk/Reward Index Indicators
80
Indicator Weightings
81

The Spain Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Spain Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Spain pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Spain, to test other views - a key input for successful budgeting and strategic business planning in the Spanish pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Spanish pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Spain.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.